Latent Pathogen Reactivation During Six-Monthly Rituximab Therapy in Children with Idiopathic Nephrotic Syndrome: A Retrospective Cohort Study
Authors:
Preprint
- 24 February 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Six-monthly rituximab therapy is increasingly used to maintain remission in children with idiopathic nephrotic syndrome. Data on infection safety, particularly patterns of latent pathogen reactivation, remain limited. Methods In this retrospective, self-controlled study, 110 children with idiopathic nephrotic syndrome received rituximab (375 mg/m²) every six months. Clinical and laboratory data were collected from 12 months before to 24 months after treatment. Infection events and pathogen status were independently adjudicated by infectious disease specialists. Results During follow-up, no cases of clinically overt Epstein–Barr virus, cytomegalovirus, hepatitis B virus, or tuberculosis infection were observed. Transient and clinically silent changes in latent infection markers occurred without progression to active disease. Two patients (1.8%) developed invasive fungal pneumonia caused by Pneumocystis jirovecii or Candida albicans , both in the setting of concomitant immunosuppressive therapy. Within 12 months after rituximab initiation, 22 children (20%) experienced common infections, predominantly involving the respiratory tract. The most frequently identified pathogens were Streptococcus pneumoniae and influenza virus. In exploratory multivariable analyses, female sex and steroid-resistant nephrotic syndrome were associated with a higher risk of infection. Rituximab-associated B-cell depletion and reductions in immunoglobulin G were reversible over time, and liver and kidney function remained stable. Conclusions In this single-center cohort, a fixed six-monthly rituximab regimen was not associated with clinically significant activation of latent viral or mycobacterial infections under systematic monitoring. Respiratory infections and invasive fungal disease, particularly in the presence of concomitant immunosuppression, remain important clinical considerations.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- Clinical practice guidelines for rituximab treatment in children with steroid-sensitive nephrotic syndromeWorld Journal of Pediatrics, 2025
- KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in ChildrenKidney International, 2025
- An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndromeKidney International, 2024
- Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndromePediatric Nephrology, 2023
- Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN surveyPediatric Nephrology, 2023
- The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndromePediatric Nephrology, 2022
- Idiopathic nephrotic syndrome in childrenThe Lancet, 2018
- Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future DirectionsGastroenterology, 2017
- Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet, 2014
- Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesisNature Clinical Practice Rheumatology, 2007